Evidence map›Paper›PMID 31978341›Full record

ArticleCell2020

Bacteriophage Prevents Alcoholic Liver Disease.

Melis Çolakoğlu, Jing Xue, Mirko Trajkovski

Abstract readComment
PubMed Publisher
In one paragraph

Article in Cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Gut microbiome and liver diseases.Fundamental research · 2025
    Review
  4. Review
  5. ProbioticFrontiers in microbiology · 2022
    Article
  6. Article
  7. Engineered Bacteriophage Therapeutics: Rationale, Challenges and Future.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2021
    Review
  8. Article
  9. Review
  10. Characterization of the Bacteriophage vB_EfaS-271 InfectingInternational journal of molecular sciences · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Melis ÇolakoğluDepartment of Cell Physiology and Metabolism, Centre Médical Universitaire (CMU), Faculty of Medicine, University of Geneva, 1211 Geneva, Switzerland; Diabetes Center, Faculty of Medicine, University of Geneva, 1211 Geneva, Switzerland.
Jing XueDepartment of Cell Physiology and Metabolism, Centre Médical Universitaire (CMU), Faculty of Medicine, University of Geneva, 1211 Geneva, Switzerland; Diabetes Center, Faculty of Medicine, University of Geneva, 1211 Geneva, Switzerland.
Mirko TrajkovskiDepartment of Cell Physiology and Metabolism, Centre Médical Universitaire (CMU), Faculty of Medicine, University of Geneva, 1211 Geneva, Switzerland; Diabetes Center, Faculty of Medicine, University of Geneva, 1211 Geneva, Switzerland. Electronic address: mirko.trajkovski@unige.ch.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alcoholic hepatitis is a severe alcohol-associated liver disease with minimal treatment options. A recent study by Duan et al. uncovers that the exotoxin-secreting gut bacterium Enterococcus faecalis is a critical contributor to alcoholic hepatitis. This bacterium can now be eliminated with a bacteriophage, suggesting a new way to treat this life-threatening disease.

Indexed as

BacteriophagesGastrointestinal MicrobiomeHepatitis, AlcoholicLiver Diseases, AlcoholicEnterococcus faecalisHumans

Identifiers

PMID31978341

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.